PURPOSES: We evaluated the prevalence and factors associated with polypharmacy and investigated the role of polypharmacy as a predictor of length of hospital stay and in-hospital mortality. METHODS: Thirty-eight internal medicine wards in Italy participated in the Registro Politerapie SIMI (REPOSI) study during 2008. One thousand three hundred and thirty-two in-patients aged ≥65 years were enrolled. Polypharmacy was defined as the concomitant use of five or more medications. Linear regression analyses were used to evaluate predictors of length of hospital stay and logistic regression models for predictors of in-hospital mortality. Age, sex, Charlson comorbidity index, polypharmacy, and number of in-hospital clinical adverse events (AEs) were used as possible confounders. RESULTS: The prevalence of polypharmacy was 51.9% at hospital admission and 67.0% at discharge. Age, number of drugs at admission, hypertension, ischemic heart disease, heart failure, and chronic obstructive pulmonary disease were independently associated with polypharmacy at discharge. In multivariate analysis, the occurrence of at least one AE while in hospital was the only predictor of prolonged hospitalization (each new AE prolonged hospital stay by 3.57 days, p < 0.0001). Age [odds ratio (OR) 1.04; 95% confidence interval (CI) 1.01-1.08; p = 0.02), comorbidities (OR 1.18; 95% CI 1.12-1.24; p < 0.0001), and AEs (OR 6.80; 95% CI 3.58-12.9; p < 0.0001) were significantly associated with in-hospital mortality. CONCLUSIONS: Although most elderly in-patients receive polypharmacy, in this study, it was not associated with any hospital outcome. However, AEs were strongly correlated with a longer hospital stay and higher mortality risk.
PURPOSES: We evaluated the prevalence and factors associated with polypharmacy and investigated the role of polypharmacy as a predictor of length of hospital stay and in-hospital mortality. METHODS: Thirty-eight internal medicine wards in Italy participated in the Registro Politerapie SIMI (REPOSI) study during 2008. One thousand three hundred and thirty-two in-patients aged ≥65 years were enrolled. Polypharmacy was defined as the concomitant use of five or more medications. Linear regression analyses were used to evaluate predictors of length of hospital stay and logistic regression models for predictors of in-hospital mortality. Age, sex, Charlson comorbidity index, polypharmacy, and number of in-hospital clinical adverse events (AEs) were used as possible confounders. RESULTS: The prevalence of polypharmacy was 51.9% at hospital admission and 67.0% at discharge. Age, number of drugs at admission, hypertension, ischemic heart disease, heart failure, and chronic obstructive pulmonary disease were independently associated with polypharmacy at discharge. In multivariate analysis, the occurrence of at least one AE while in hospital was the only predictor of prolonged hospitalization (each new AE prolonged hospital stay by 3.57 days, p < 0.0001). Age [odds ratio (OR) 1.04; 95% confidence interval (CI) 1.01-1.08; p = 0.02), comorbidities (OR 1.18; 95% CI 1.12-1.24; p < 0.0001), and AEs (OR 6.80; 95% CI 3.58-12.9; p < 0.0001) were significantly associated with in-hospital mortality. CONCLUSIONS: Although most elderly in-patients receive polypharmacy, in this study, it was not associated with any hospital outcome. However, AEs were strongly correlated with a longer hospital stay and higher mortality risk.
Authors: Michael A Steinman; C Seth Landefeld; Gary E Rosenthal; Daniel Berthenthal; Saunak Sen; Peter J Kaboli Journal: J Am Geriatr Soc Date: 2006-10 Impact factor: 5.562
Authors: Martin Wawruch; Martina Zikavska; Ladislava Wsolova; Magdalena Kuzelova; Jana Tisonova; Jan Gajdosik; Karel Urbanek; Viera Kristova Journal: Pharm World Sci Date: 2007-10-18
Authors: Jochen Schuler; Christina Dückelmann; Wolfgang Beindl; Erika Prinz; Thomas Michalski; Max Pichler Journal: Wien Klin Wochenschr Date: 2008 Impact factor: 1.704
Authors: F Sganga; D L Vetrano; S Volpato; A Cherubini; C Ruggiero; A Corsonello; P Fabbietti; F Lattanzio; R Bernabei; G Onder Journal: J Nutr Health Aging Date: 2014 Impact factor: 4.075
Authors: R Vicinanza; G Troisi; R Cangemi; M U De Martino; D Pastori; S Bernardini; F Crisciotti; F Di Violante; A Frizza; M Cacciafesta; P Pignatelli; V Marigliano Journal: J Nutr Health Aging Date: 2018 Impact factor: 4.075
Authors: Aymen Ali Al-Qurain; Lemlem G Gebremichael; Mohammed S Khan; Desmond B Williams; Lorraine Mackenzie; Craig Phillips; Patrick Russell; Michael S Roberts; Michael D Wiese Journal: Int J Clin Pharm Date: 2020-11-18
Authors: Carolina Mosca; Margarida M Castel-Branco; Ana C Ribeiro-Rama; Margarida M Caramona; Fernando Fernandez-Llimos; Isabel V Figueiredo Journal: Int J Clin Pharm Date: 2013-12-01
Authors: Valeria Raparelli; Marco Proietti; Carmelo Buttà; Paolo Di Giosia; Domenico Sirico; Paolo Gobbi; Salvatore Corrao; Giovanni Davì; Anna Rita Vestri; Francesco Perticone; Gino Roberto Corazza; Francesco Violi; Stefania Basili Journal: Intern Emerg Med Date: 2014-07-03 Impact factor: 3.397